In 2018, 51.6% of subjects among 7599 colon cancer patients showed KRAS mutations, and overexpression of HER2 was shown in 62.5% of mutated KRAS patients (P=0.02). This evidence concerns the gene ERBB2 and malignant colon neoplasm.